Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway
- PMID: 36762472
- PMCID: PMC10301241
- DOI: 10.1080/0284186X.2023.2175331
Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway
Abstract
Background: The Prostate Cancer Cohort Consortium (PC3) Working Group proposed a definition for aggressive prostate cancer (PC) for aetiologic epidemiologic research. We aimed to validate this definition as well as a second approach utilising only information on stage at diagnosis.
Methods: First primary PCs diagnosed 2004 - 2009 in the population-based Janus Serum Bank (JSB) cohort were identified by linkage to the population-based Cancer Registry of Norway (CRN) (n = 3568). The CRN and Norwegian Prostate Cancer Registry provided clinicopathological data for these cases. Approach 1 classified PC as aggressive if it was clinically T4, or N1, or M1, or had a Gleason score ≥8 at diagnosis (as proposed). Approach 2 classified PC as aggressive if CRN stage at diagnosis was 'regional spread' or 'distant metastases'. Both approaches were validated by calculating the sensitivity and positive predictive value (PPV) against PC-death within 10 years of diagnosis.
Results: Overall, 555 died from PC within 10 years. Approach 1 classified 24.7% of cases as aggressive and 13.6% were unclassified due to missing information. Approach 2 classified 19.6% as aggressive and 29% were unclassified. Sensitivity was highest for Approach 1 (0.76, 95% CI: 0.72 - 0.80 vs 0.69, 95% CI: 0.64 - 0.73), while PPVs were similar for both approaches (0.43, 95% CI: 0.40 - 0.46 and 0.40, 95% CI: 0.36 - 0.44). We observed similarly high sensitivity and higher PPVs than those reported by the PC3 Working Group.
Conclusions: The proposed definition of aggressive PC was applicable and valid in the JSB cohort. Stage at diagnosis can be useful if data on cTNM or Gleason score is unavailable.
Keywords: Classification; aggressive prostate cancer; population-based cohort; registry data.
Conflict of interest statement
Author disclosures: No conflicts of interest
Figures
References
-
- Ferlay JEM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today International Agency for Research on Cancer, Lyon, France; 2020. [Cited 2021 Jul 07 ]. Available from: https://gco.iarc.fr/today/home.
-
- Lavi A, Cohen M. [PROSTATE CANCER EARLY DETECTION USING PSA - CURRENT TRENDS AND RECENT UPDATES]. Harefuah. 2017;156(3):185–188 - PubMed
-
- Torre LA, Siegel RL, Ward EM, et al. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27 - PubMed
-
- Cancer Registry of Norway. Cancer in Norway 2020 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2021.
-
- Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195–200 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous